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CYCLOSPORIN A, the most promising new immu-
nosuppressive agent of recent years, is an extract 
from the fungi Cylindrocarpon lucidum and 
Trichoderma polysporum. It was discovered 
by Dreyfuss and associates (10), characterized 
biochemically by Ruegger (17) and Petcher (15) 
and their associates, and shown to be immuno-
suppressive by Borel and colleagues (2, 3, 4). 
The studies by Borel and colleagues (2, 3, 4) of 
cyclosporin A in mice, rats and guinea pigs were 
quite complete. With multiple test systems, in-
cluding skin homotransplantation, Borel and col-
leagues (2, 3, 4) showed that cyclosporin A de-
pressed humoral and cellular immunity, that it 
had a preferential and quickly reversible action 
against T lymphocytes and that these effects were 
not accompanied by bone marrow depression or 
other prohibitive organ toxicity. The ability of 
cyclosporin A to prevent or delay rejection of 
hearts, kidneys, livers or pancreases was prompt-
ly shown in rats, rabbits, dogs and pigs by Kosta-
kis (13), CaIne (7, 8, 9) and Green (11) and 
their associates. 
An evaluation of cyclosporin A in human 
recipients of kidneys, pancreases and livers has 
been reported by CaIne and collaborators (5, 6) . 
The ability of the drug to prevent irreversible 
rejection without ancillary steroid therapy was 
striking. However, CaIne and co-workers (5, 6) 
concluded that unexpectedly severe nephrotoxici-
ty was responsible for a high incidence of anuria 
shortly after renal transplantation and for abnor-
mal late graft function in the majority of the kid-
ney recipients. Furthermore, the administration 
of other drugs, including steroids, proved to be so 
dangerous that their chronic use was thought not 
to be advisable. 
Our own early observations in 22 consecutive 
cadaveric renal transplant recipients treated with 
cyclosporin A have been interpreted differently. 
We have concluded that many of the early and 
delayed perturbations of kidney graft function in 
the patients in our series were manifestations of 
immunologic rejection rather than drug toxicity, 
that the appropriate treatment frequently was 
with steroids and that the maximum short term 
and long term value of cyclosporin A could not be 
realized without such combination therapy. So 
far, cyclosporin A and prednisone have been safe 
when used together, even in patients who were 
prepared for transplantation by prolonged tho-
racic duct drainage. 
METHODS 
The mean patient age was 37±8, S.D., years, 
with a range of 26 to 48 years (Table I) . The 22 
recipients included four who were undergoing re-
transplantation after the rejection at an earlier 
time of one or more kidneys. Two of the patients From the Department of Surgery, Denver Veterans Administra-
tion Medical Center and the School of Medicine of the University had diabetes. 
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FIG. 1. A typical example of post-transplantation oliguria which became most 
severe on day 4 in Patient 7. Cyclosporin A in daily doses of 17.5 milligrams per 
kilogram was begun one day before transplantation. With the apparent rejection, 
there was progressive graft swelling, pain and tenderness. Thcse findings as well as 
low grade fever and oliguria were relieved promptly by a single bolus of methyl-
prednisolone given intravenously. Nine days later, maintenance dosages of predni-
sone were started orally. 
available. The serums of seven recipients con-
tained warm cytotoxic antibodies against the B or 
T lymphocytes, or both, of at least 20 per cent of a 
panel of 30 normal volunteers (12, 23). No 
transplantations were carried out across a POSi-
tive warm T-cell cross match. 
Mechanical Lymphoid Depletion 
Using previously described techniques (22), 
ten of the 22 patients had thoracic duct drainage 
for 14 to 84 days before transplantation (Table 
I) and for one to 36 days thereafter. The total 
number of lymphocytes removed ranged from 49 
to 376XI09 with a mean of 140±82, S.D., XlO" 
One recipient had removal of blood lymphocytes 
by Iymphapheresis five times a week for seven 
weeks. The total number of lymphocytes removed 
during this time was 94XI09• 
C.vc!osporm A Schedule 
For the 11 patients prepared with lymphoid 
depletion, cyclosporin A was given orally six to 12 
hours before transplantation in a dose of 17.5 
milligrams per kilogram and continued at this 
dose given orally once daily thereafter. Postoper-
atively, all recipients ate promptly, making par-
enteral administration unnecessary. 
The 11 recipients not prepared with lymphoid 
depletion were pretreated instead with daily dos-
ages of cyclosporin A given orally for one to 
18 days, as shown in Table I, average 8.7. The 
daily dose was usually 17.5 milligrams per kilo-
gram. 
Two months after transplantation, or some-
times before this, if nephrotoxicity was suspected, 
the patients were considered for an adjustment of 
the maintenance doses of cyelosporin A but only 
in some were the changes actually made. The 
present daily dosages of cyclosporin A after two to 
four and one-half months are summarized in Ta-
ble I. 
Rejection and Steroid Therapy 
Steroid therapy was not given initially in eight 
patients, and in 14 others, a single intravenous 
bolus of 1 gram methylprednisolone was given 
during transplantation. Maintenance steroids 
were started later, usually because rejection was 
suspected. 
Rejection was diagnosed if renal failure re-
curred in the early postoperative period in the ab-
sence of technical complications. Declining urine 
volume, graft swelling with wound tenderness 
and fever were signals for urgent therapy with in-
travenously administered 1 gram doses of methyl-
prednisolone or 0.1 to 1.0 gram doses of hy-
drocortisone. The presence of only one of these 
three findings was not always accompanied by in-
creases in serum creatinine and blood urea ni-
trogen values. However, recurrent uremia almost 
always could be documented if two, or all three, 
components of the triad were present. Radionu-
elide scanning was performed at regular intervals 
and was particularly helpful in observing the 
course of patients whose grafts went through pe-
riods of nonfunction. 
When rejection was diagnosed, the first pa-
tients were treated with steroid bolus therapy 
alone (Figs. 1 and 2). Later in the series, the in-
travenous bolus of methylprednisolone or hydro-
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FIG. 2. The course of Patient 5 whose first cadaveric transplant in 1977 was rejected after 21 days. 
A second transplant was also rejected with azathioprine and prednisone therapy despite 30 days pre-
treatment with thoracic duct drainage. A third transplant was performed 50 days after the unsuc-
cessful second transplantation. The patient was switched from azathioprine to cyclosporin A at that 
time, prednisone was stopped and thoracic duct drainage was discontinued two days later after a to-
tal of 82 days. See text for discussion. D, Dialysis; NIP, methylprednisolone, 1 gram intravenously. 
cortisone was followed with a short course of 
prednisone given orally, beginning at 200 or 160 
milligrams per day and reducing this by 40 milli-
grams per day until 40 milligrams were reached. 
On the succeeding one or two days, the amount of 
prednisone was further reduced to a maintenance 
level of 10 to 20 milligrams per day, as shown in 
Figure 3. 
Rejection Versus Nephrotoxicity 
Response to therapy was the main determinant 
in making this distinction. When failing renal 
function, wound tenderness, graft enlargement 
and fever or various combinations of these find-
ings were quickly ameliorated in the early post-
operative period by steroid therapy, the patient 
was considered to have had an acute rejection. If 
imperfect renal function weeks or months after 
transplantation was promptly improved by the 
institution of steroid therapy, indolent rejection 
was judged to have been present. 
Nlajor changes in the cyclosporin A dosages 
were also made for combined diagnostic and ther-
apeutic purposes. Occasionally, cyclosporin A 
was increased from the starting daily dose of 17.5 
to 25 milligrams per kilogram. 1\lore commonly, 
the daily dose was reduced to 10 milligrams per 
kilogram or less. If the latter change resulted in 
improved renal function, it was considered that 
nephrotoxicity had been present. 
Such drug manipulation for diagnosis was 
meaningful only when all treatment factors ex-
cept one were kept stable. Thus, the cyclosporin 
A dosages were fixed during times of steroid 
change, and conversely, the steroid dosages were 
not altered during times of cyclosporin A adjust-
ment. 
RESL:LTS 
Patient 5;uruival 
One of the 22 recipients died within the first 
two to four and one-half months. This patient was 
a 45 year old man who died five weeks after 
primary cadaveric transplantation. Definite kid-
ney rejection never occurred, and the highest dai-
ly dose of prednisone after transplantation was 15 
milligrams. Four days before death, a triple cor-
onary artery bypass was performed to relieve car-
diac symptoms which had predated transplanta-
tion but which had been misinterpreted at the 
earlier time. Re-exploration was required be-
cause of intrathoracic hemorrhage. After this, 
hypotension and heart failure became irreversi-
ble. Permission for performing an autopsy was 
denied. 
Insofar as could be determined, cyclosporin A 
did not contribute to the death. Platelet counts 
and other coagulation measurements were nor-
mal prior to the revascularization of the coronary 
arteries. 
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FIG. 3. Use of a short course of orally administered prednisone leading 
within five to seven days to maintenance therapy with 10 to 20 milli-
grams per day. This use of prednisone has been referred to as minicycle 
therapy. The daily dose of cyclosporin A was always 17.5 milligrams per 
kilogram. 
Kidney Survival 
In addition to the renal graft in the patient who 
died, two other kidneys were lost. Both were in 
patients undergoing retransplantation six to 18 
months after rejection of the primary grafts. One 
of the recipients who was pretreated for 24 days 
with thoracic duct drainage was given a kidney 
that developed complete ureteral necrosis. After 
three unsuccessful attempts at reconstruction, the 
grossly normal organ was removed 16 days after 
transplantation. Thoracic duct drainage as well 
as cyclosporin A was continued for another 60 
days when a repeat transplantation was success-
fully performed. The latest graft has not been 
considered in the results. Histopathologically, the 
graft which was excised after 16 days had rela-
tively few abnormalities. There were scattered, 
small groups of infiltrating mononuclear cells in 
the interstitium. Similar cells were present in 
some of the peri tubular capillaries. Less than 5 
per cent of the mononuclear cells were lympho-
blasts. The arterioles and arteries were normal. A 
few of the superficial cortical glomeruli contained 
increased amounts of mesangial matrix. 
The third graft loss was in a 27 year old 
woman who earlier had rejected a kidney from a 
perfectly matched sibling donor. The cadaveric 
kidney transplanted with cyclosporin A treatment 
hecame oliguric within a few days. The patient 
had steroid, as well as cyclosporin A, therapy 
stopped after 44 days because a bleeding gastric 
ulcer developed. The homograft was removed two 
days later. The kidney was somewhat edematous, 
but it was pink, uniformly vascularized and not 
obviously rejected by gross criteria. 
Histopathologically, there was evidence of cell 
mediated rejection as well as humoral rejection. 
The interstitium of the transplant contained 
many scattered, small to medium sized groups of 
infiltrating mononuclear cells. Similar cells were 
present in most of the peritubular capillaries. 
About 20 per cent of these infiltrating cells were 
lymphoblasts. Some of the intralobular and ar-
cuate arteries were narrowed by intimal thicken-
ing associated with rupture of the internal elastic 
lamina. A few arteries were completely occluded. 
Ischemic changes were present in 15 per cent of 
the glomeruli, and 1 per cent were end-stage 
sclerotic. 
Nineteen of the 22 original homografts treated 
with cyclosporin A are life-supporting. The func-
tion after two to four and one-half months is in-
dicated in Table 1. 
Among the 18 primary cadaveric grafts, the 
only loss was by the patient death, leaving 17 of 
these primary cadaveric organs still working. The 
other two graft losses were among the four grafts 
used for retransplantation. 
Early Rejection 
All 22 of the cadaveric kidneys had prompt 
diuresis. Function thereafter was highly variable. 
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FIG. 4. Courses of Patient 3, top, and Patient 2, bottom, 
show acute rejection 38 and 45 days, respectively, after 
transplantation. No significant changes in urine output, 
body weight or temperature were recorded. Doses of cyclo-
sporin A were 17.5 milligrams per kilogram per day 
throughout. Renal scans always revealed good flow, but 
there was decreased Hippuran, sodium o-iodohippurate, 
clearance before, during and after the aforementioned epi-
sodes. Note the declines in creatinine level after institution of 
low dosages of prednisone. 
Fifteen of the 22 patients subsequently had what 
was diagnosed as definite acute rejection, most 
commonly occurring within the first week. One 
other recipient may have had early rejection, but 
the findings were equivocal. 
The features of rejection that occurred within 
the first week (Fig. 1) often included oliguria, 
wound tenderness, graft swelling, fever and pro-
found fatigue in addition to secondary increases 
of serum creatinine concentration and the blood 
urea nitrogen value. Not all elements of the syn-
drome were present in every patient, but those 
which were proved remarkably susceptible to 
steroid therapy. The systemic complications of 
fever and malaise could be relieved with as little 
as 100 milligrams of hydrocortisone, although 
1,000 milligrams of hydrocortisone or, alterna-
tively, 1,000 milligrams of methylprednisolone 
usually were given (Fig. 1). In most instances, 
this minimal adjuvant treatment either improved 
or stabilized renal function. 
Rejection with the use of cyclosporin A did not 
proceed to graft necrosis, even when, in retro-
spect, the steroid therapy was suboptimal. The 
patient whose course is shown in Figure 2 
frequently responded with a transient increase of 
urine output after a 1 gram bolus of intravenously 
administered methylprednisolone, but consistent 
life-supporting renal function was not obtained 
until maintenance therapy was begun with 30 
milligrams per day of prednisone. In spite of the 
two and one-half week delay in providing appro-
priate maintenance steroids, a satisfactory result 
was eventually obtained. 
. A pos.sible explanation for the dogged viability 
of reJectmg homografts was observed in radionu-
clide scans. A typical finding was maintenance of 
good homograft blood flow but with poor excre-
tion. Rarely seen were the declines in homograft 
blood flow which have been empirically associat-
ed with rejection by Stables and co-authors (18) 
and other authorities under conditions of conven-
tional immunosuppression. 
As it became obvious that rejection was a 
frequent problem in the early postoperative peri-
od, the burst of oral prednisone therapy added to 
the intravenous pulse therapy (Fig. 3) provided 
better immunologic control and a reduced neces-
sity postoperatively for temporary hemodialysis. 
Thus, five of the first 13 patients had to be sup-
ported with dialysis after undergoing transplan-
tation compared with only one of the last nine pa-
tients. 
Late Rejection 
Four patients who were discharged from the 
hospital receiving therapy with cyclosporin A 
alone, and three more, who had low dose steroid 
therapy as well, had slow, subsequent deteriora-
tion of renal function. Graft function became bet-:-
ter when prednisone was begun or was increased 
from the preceding level (Fig. 4). Because of the 
steroid responsiveness, it was concluded that de-
layed rejection had occurred. 
Nephrotoxicity 
Because of the high incidence of significant 
albeit highly treatable rejection, an effort was 
made to maintain the dose of cyclosporin A at the 
high level of about 17.5 milligrams per kilogram 
per day for at least the first two postoperative 
months, even if nephrotoxicity was suspected. If 
a reduction in the dosage of cyclosporin A was 
followed by an improvement in renal function, it 
was concluded that nephrotoxicity had been 
responsible for the graft dysfunction. This chain 
of events was observed in seven of the 22 patients 
(Fig. 5) who are identified in Table I as Patients 
3, 4, 5, 11, 13, 21 and 22. 
Pretreatment, Eventual Function and Steroids 
The renal graft function and steroid treatment 
in each patient after two to four and one-half 
months are summarized in Table I. By clinical 
assessment, the best results occurred in the 11 pa-
tients who had preoperative conditioning by lym-
phoid depletion. The only kidney loss was from 
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FIG. 5. An example of cyclosporin A nephrotoxicity is shown in 
the course of Patient 4. The cyclosporin A dosage was at first in-
creased with resulting rises in the creatinine and blood urea ni-
trogen levels. Note that both measures returned toward normal 
within a few days after reducing cyclosporin A dose to 9 milligrams 
per kilogram per day. The prednisone dose was kept at 15 milli-
grams per day throughout the time shown. 
homograft ureteral necrosis in a recipient who 
was given a successful subsequent transplant. 
Rejection usually was not severe in the patients 
prepared by lymphoid depletion, and early ster-
oid requirements were minimal. 
However, the results were also excellent in the 
11 patients who did not have lymphoid depletion 
but who were pretreated for one to 18 days with 
cyclosporin A. There was no obvious difference in 
patients pretreated with cyclosporin A for a brief, 
as opposed to a longer, time (Table I). Although 
there was one death among the 11 patients not 
prepared by lymphoid depletion, the mortality 
was not related to the transplantation. One graft 
was lost to rejection. 
Extrarenal ToxZ:city of Cyclosporin A 
Cyclosporin A was well tolerated orally. Many 
patients had a flushing sensation of the abdomen, 
face, neck or total body within an hour after in-
gesting the drug. Examples were also seen of the 
minor hirsutism, gum hyperplasia and tremor 
that have been described by CaIne (5, 6) and 
Pow les (16) and their associates. There were no 
examples of leukopenia or other evidence of bone 
marrow depression. 
In six of the 22 recipients, hepatic dysfunction 
developed with the use of cyclosporin A, always 
when the high daily dose of about 17.5 milligrams 
per kilogram was being given Crable I) . All six 
of the patients became chemically jaundiced with 
peak serum bilirubin levels of 1.9 to 6.6 milli-
grams per cent. There were also increases in se-
rum transaminase and alkaline phosphatase 
values and prothrombin times, but the patients 
were asymptomatic. When the daily dose of cy-
closporin A was reduced to 10 milligrams per 
kilogram or less, the liver function abnormalities 
regressed. Two of the 22 patients who were 
known HRAg carriers and who were suspected 
of having chronic aggressive hepatitis did not 
have hepatic complications with cyclosporin A 
therapy. These were Patients 1 and 17 as de-
scribed in Table I. 
No lymphomas or other malignant tumors 
were observed. There were three significant in-
fections, of which at least two and possibly all 
three preceded cyclosporin A treatment. In one 
patient, nocardia infection developed in the lung 
which was treated with erythromycin and am-
picillin. Another recipient with probable acti-
vation of colonic amebiasis was treated with 
metronidazole. A third patient with pleural gran-
ulomas and possibly active tuberculosis is under-
going treatment with isoniazid, rifampin and 
ethambutol. 
DISCUSSION 
The exceptional effectiveness and safety of cy-
closporin A were evident throughout these early 
trials. The only death among the first 22 cadaver-
ic kidney recipients was from a cardiac surgical 
complication that seemingly had no relation to the 
renal transplantation. There have been no other 
life-threatening complications in the follow-up 
periods of two to four and one-half months. 
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All but three of the original 22 transplants are 
functioning well, and in one patient, whose orig-
inal graft had ureteral necrosis, a second organ 
was provided a few weeks later. Thus, all but two 
of the 22 recipients have been liberated from 
dialysis. Seventeen grafts survived in the 18 pa-
tients receiving kidney transplants for the first 
time, the only loss being from the cardiac surgical 
death. 
Such a high rate of success was not attributable 
to cyclosporin A alone. As was the case with 
azathioprine nearly 20 years ago (19, 21) , steroid 
therapy provided the means for rapid adjustments 
in immunosuppression, especially in the first post-
operative days and also subsequently in patients 
whose renal function was subnormal after one or 
two months. The difference from past experience 
with conventional immunosuppression was that 
with cyclosporin A, the steroid component of com-
bined immunosuppression was only a small frac-
tion of that required in the past to achieve inferior 
results at considerable risk to life. 
The divergence of our views from those of 
CaIne and co-authors (5, 6, 8) concerning the 
role and value of steroid therapy hinges on the 
question of whether episodes of sudden postoper-
ative renal failure have been due to rejection or to 
cyclosporin A nephrotoxicity. The paucity of his-
topathologic findings in graft biopsies convinced 
CaIne and associates (5, 6, 8) that rejection was 
not the explanation. If biopsies of the kidneys had 
been obtained in our recipients, there is no reason 
to believe that major stigmas of rejection would 
have been different from the samples of CaIne 
and colleagues (5, 6, 8). In the patients in our 
series with acute graft failure, radionuclide scans 
usually showed such good blood flow to the poor-
ly excreting transplants that the most traditional 
diagnosis on strict but empirically derived radio-
logic criteria would have been acute tubular ne-
crosis. 
Yet, the therapeutic response to prednisone or 
even to hydrocortisone was so dramatic as to leave 
little doubt about an immunologic component of 
these crises. In patients in whom the grafts deteri-
orated at a later time, the improvement of renal 
function that followed the institution of as little as 
10 milligrams per day of prednisone was equally 
convmcmg. 
Nevertheless, a background role of drug tox-
icity may have been contributory. An argument 
could be mounted that the clinical manifestations 
of histopathologically and hemodynamically mi-
nor rejections were amplified by underlying cy-
closporin A nephrotoxicity of the kind seen by 
Powles and co-workers (16) in their bone mar-
row transplant recipients. There were seven 
examples in our experience of moderately im-
paired renal function which five weeks to three 
months after transplantation returned toward 
normal when the daily dosage of cyclosporin A 
was abruptly reduced. Clearly, some such exper-
imentation may be necessary in individual pa-
tients to arrive at a differential diagnosis between 
rejection and nephrotoxicity. 
With the combination of cyclosporin A and 
prednisone, it will be desirable to minimize the 
moment to moment judgments that have dictated 
the timing and extent of the steroid treatment. 
Now that it is known that prednisone usually will 
be required for cadaveric kidney recipients in ad-
dition to cyclosporin A, we plan in some, and pos-
sibly most, future patients to provide a five or six 
day burst of steroid therapy similar to that shown 
in Figure 3, but beginning on the day of trans-
plantation and ending with a small daily main-
tenance dose of 10 or 20 milligrams. The ration-
ale for this use of steroids is analogous to that 
advanced many years ago for the prophylactic 
administration of prednisone with azathioprine 
(19) . 
As clinical trials with cyclosporin A expand, 
flexibility of planning and purpose will be impor-
tant. Randomized trials have been proposed com-
paring cyclosporin A alone with conventional 
treatment by azathioprine and prednisone. Yet, 
our experience herein reported suggests that the 
use of cyclosporin A as the sole treatment would 
be suboptimal. More pilot studies seem necessary 
with combination therapy, but if the results 
remain as good as they have been in our trial, and 
with as much freedom from chronic steroid mor-
bidity, it will be difficult within the limits of in-
formed consent to find control patients to undergo 
so-called conventional treatment with azathio-
prine and prednisone (19, 21) or azathioprine, 
prednisone and antilymphocyte globulin (20). 
An admonition not to begin randomized trials 
with cyclosporin A before learning how to use the 
drug properly would have seemed foolish a few 
years ago before the reflex acceptance of all such 
trials. However, as the clinical application of cy-
closporin A widens, there will be questions, such 
as the prophylactic administration of steroids, 
that will be susceptible to investigadon by ran-
domization. Inquiries about recipient pretreat-
ment also will be important. The value of pre-
treatment has been emphasized by our own 
studies of thoracic duct drainage (22). In an ap-
plication of the pretreatment principle delineated 
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by that experience, half of the patients in the se-
ries herein reported were prepared for transplan-
tation by thoracic duct drainage or lymphaphere-
sis to which the first dosage of cyclosporin A was 
added a few hours preoperatively. The other 11 
patients were preconditioned instead with cyclo-
sporin A for one to 17 days. There were no strik-
ing differences in the results between the two 
groups. It is not even certain if eitherEretreat-
ment technique was better than if cyclosporin A 
had been instituted on the day of transplantation 
with no prior therapy. 
Of far greater importance than defining the 
preoperative value of cyclosporin A will be delin-
eation of its chronic postoperative use. So far, the 
use of cyclosporin A in the patients in our series 
has proved to be so safe that we plan to continue it 
indefinitely. There has been no bone marrow 
depression, little serious hepatotoxicity and few 
complaints about gum hyperplasia, hirsutism and 
tremors. No new tumors have been seen, such as 
described by CaIne and associates (5) in humans 
and by Bieber and colleagues (1) in subhuman 
primates. Within the 34 patients treated by CaIne 
and collaborators (5), the 23 bone marrow 
recipients reported by Powles and co-authors 
(16) and the 22 patients of the present series, 
there were three lymphomas for a de novo tumor 
incidence of 3.8 per cent. Both the frequency of 
new tumors and the disproportionate number of 
lymphomas have been comparable with those in 
our kidney recipients (20) and those reported by 
Penn (14) who were treated with azathioprine 
and prednisone with or without antilymphocyte 
globulin. 
Sl'MMARY 
Eighteen patients were treated with primary 
cadaveric renal transplantation using,cyclosporin 
A therapy, and four more patients underwent 
cadaveric retransplantation. Eleven of the 22 
recipients were conditioned with lymphoid deple-
tion before transplantation, using thoracic duct 
drainage or lymphapheresis for two to eight and 
one-half weeks. Cyclosporin A was begun a few 
hours before grafting. The other 11 patients were 
pretreated with cyclosporin A for from one day to 
18 days. 
After transplantation, the majority of patients 
in both suhgroups of 11 had rejection develop, but 
in most, the immunologic process was readily 
controlled with relatively small dosages of pred-
nisone. After follow-up periods of two to four and 
one-half months, one patient has died of the com-
plications of a coronary artery reconstruction that 
was not related to the transplantation. Another 
graft was lost from rejection, and a third organ 
was removed because of ureteral necrosis. Nine-
teen of the original 22 cadaveric kidneys are func-
tioning, including 17 of the 18 kidneys given to 
patients who were undergoing transplantation 
for the first time. The only loss in the latter group 
of 18 patients was in the patient who died after an 
open heart operation. 
Results of these studies have shown that cyclo-
sporin A is a superior and safe immunosuppres-
sive drug but that, for optimal use in cadaveric 
transplantation, it usually should not be given 
alone. Steroid therapy greatly amplified the value 
of cyclosporin A. Unless major delayed morbidity 
develops which is not obvious so far, this drug 
combination should permit revolutionary ad-
vances in the transplantation of all organs. Other 
adjuncts to the cyclosporin A-steroid combina-
tion, including lymphoid depletion techniques, 
will require further investigation. 
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